David R. D’Adamo

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

33h-index6.7kcitations83works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(48), Vascular Tumors and Angiosarcomas(21), Gastrointestinal Tumor Research and Treatment(13), Gastric Cancer Management and Outcomes(11), Cancer Treatment and Pharmacology(9)

Publications83 total

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data.
Journal of Clinical Oncology·2025
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
EClinicalMedicine·2023· 92 citedOpen Access
Data from Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
2023Open Access
Supplementary Table 1 from The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
2023Open Access
Data from The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
2023Open Access
Supplementary Information from Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
2023Open Access
Data from Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
2023· 1 citedOpen Access
Supplementary Table 1 from The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
2023Open Access
Supplementary Information from Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
2023Open Access
Data from The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
2023Open Access
Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Journal of Clinical Oncology·2022· 3 cited
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Journal of Clinical Oncology·2021· 73 cited
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Clinical Cancer Research·2021· 135 citedOpen Access
A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
Journal of Clinical Oncology·2020· 39 cited
A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.
Journal of Clinical Oncology·2020· 2 citedOpen Access
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
European Journal of Cancer·2019· 28 citedOpen Access
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
British Journal of Cancer·2019· 41 citedOpen Access
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors
The Oncologist·2018· 22 citedOpen Access
A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Pediatric Blood & Cancer·2018· 18 citedOpen Access
Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity
BMJ Case Reports·2018· 8 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Robert G. Maki(30), Mary Louise Keohan(16), Gary K. Schwartz(13), Cristina R. Antonescu(12), George D. Demetri(8), James E. Butrynski(6), Jean‐Yves Blay(6), Samuel Singer(6), Patrick Schöffski(5), Mark A. Dickson(5), Sant P. Chawla(4), Antoîne Italiano(4), Giovanni Grignani(4), Samir D. Undevia(4), David P. Kelsen(4), Suzanne George(4), David C. Harmon(4), Jeffrey A. Morgan(4), Andrew J. Wagner(4), Linda S. Ahn(4)